Etanautine
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (December 2007) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
|
|
Etanautine
|
|
| Systematic (IUPAC) name | |
| 2-[di(phenyl)methoxy]-N,N-dimethylethanamine; 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid | |
| Identifiers | |
| CAS number | |
| ATC code | N04 |
| PubChem | ? |
| Chemical data | |
| Formula | C26H31N5O5 |
| Mol. mass | 493.555 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Etanautine (or diphenhydramine monoacefyllinate) is a anticholinergic used as an anti-parkinson drug. It is a 1:1 salt of diphenhydramine with acefylline, similar to the diphenydramine/8-chlorotheophylline combination product dimenhydrinate.
As with dimenhydrinate, the stimulant effect of the acefylline counteracts the sedative effect from the diphenhydramine, resulting in an improved therapeutic profile.
The 1:2 salt diphenhydramine diacefylline (with two molecules of acefylline to each molecule of diphenhydramine) is also used in medicine, under the brand name Nautamine.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
